Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Satish Sharma

Pain Medicine Henderson, NV Medical Doctor

NPI 1730169319 CMS profile 215073

9029 S Pecos Rd, Suite 2800, Henderson, NV 89074

Open in the dashboard

General payments

$1,070

42 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Satish Sharma of Henderson, NV is reported in the CMS Open Payments database as having received $1,070 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $305 12
2024 General $339 20
2023 General $79 1
2022 General $189 2
2021 General $35 1
2020 General $88 4
2019 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Satish Sharma
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Satish Sharma were reported at $305. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Satish Sharma Pain Medicine median Middle half National median
2019 $34 $498 $126–$1,682 $163
2020 $88 $284 $80–$910 $114
2021 $35 $399 $112–$1,219 $132
2022 $189 $455 $137–$1,484 $149
2023 $79 $484 $128–$1,495 $160
2024 $339 $498 $131–$1,540 $164
2025 $305 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BIOTRONIK NRO, Inc. $625 31 payments
  2. Boston Scientific Corporation $200 3 payments
  3. Relievant Medsystems, Inc. $79 1 payment
  4. Abbott Laboratories $66 2 payments
  5. Janssen Pharmaceuticals, Inc $43 2 payments
  6. Nevro Corp. $21 1 payment
  7. SPR Therapeutics, Inc $19 1 payment
  8. Biogen, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,070 42 payments
Products named General payments · program years 2019–2025
  1. Prospera Not Applicable $339 20 payments
  2. Prospera Not Applicable $286 11 payments
  3. General - Pain Management General - Pain Management_NMD $168 1 payment
  4. Intracept Pain $79 1 payment
  5. Intracept Pain $79 1 payment
  6. Intracept Pain $79 1 payment
  7. Intracept Pain $79 1 payment
  8. SPRAVATO $43 2 payments
  9. Proclaim IPG $35 1 payment
  10. GENERAL - PAIN MANAGEMENT Pain Management $32 2 payments
  11. Other $114 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

2,778

Median for Pain Management: 951

Drug cost

$53,293

Median for Pain Management: $26,034

Branded share of claims

43.2%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 800 $20,532
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 343 $10,783
Gabapentin Generic 432 $6,664
Oxycodone Hcl Generic 215 $3,019
Pregabalin Generic 118 $2,135
Diclofenac Sodium Generic 151 $1,587
Lidocaine Generic 15 $1,163
Morphine Sulfate Er Morphine Sulfate Brand 56 $1,077
Naloxone Hcl Generic 14 $942
Tizanidine Hcl Generic 110 $912

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$97,127

Medicare's payments for the services billed

Medicare patients

260

Average age 68

Services billed

1,254

171 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Depression 32%
Ischemic heart disease 28%
Chronic kidney disease 24%
COPD 23%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record